Glucagon-Like Peptide-1 (GLP-1) Explained

GLP-1 (glucagon-like peptide-1) is an incretin hormone released from gut L cells after food. It binds GLP-1 receptors on pancreatic beta cells (glucose-dependent insulin release), slows gastric emptying, and acts on brain centers involved in satiety. Synthetic GLP-1 receptor agonists mimic this signal for type 2 diabetes and obesity indications. Tirzepatide adds GIP co-agonism—see tirzepatide vs semaglutide.

Endogenous GLP-1 is short-lived (rapidly cleaved by DPP-4). Therapeutic peptides in this class are engineered for longer half-life (modified sequences, albumin binding, etc.). “Natural GLP-1” in search often overlaps curiosity about food and satiety; the clinical drug class is pharmacologic agonism, not a pantry ingredient.

The incretin effect—the observation that oral glucose triggers greater insulin release than equivalent IV glucose—was described in the 1960s. GLP-1 was identified as a key incretin hormone in the 1980s by researchers studying proglucagon processing in intestinal L cells.

The short half-life of native GLP-1 (approximately 2 minutes, cleaved by DPP-4) made it initially impractical as a drug. The breakthrough came from engineering DPP-4-resistant analogs (exenatide, liraglutide) and later acylated peptides (semaglutide) with albumin binding for weekly dosing.

Currently approved GLP-1 receptor agonists include exenatide (exendin-4 based, twice-daily), liraglutide (daily), semaglutide (weekly SC or daily oral), and dulaglutide (weekly). Tirzepatide adds GIP co-agonism—see mechanism comparison.

Research-grade GLP-1 analogs sold for laboratory use are not interchangeable with FDA-approved products. Purity, formulation, and regulatory status differ entirely. See what are research peptides for the RUO distinction.

GLP-1 receptors are expressed in cardiac tissue and the CNS. The SELECT trial (semaglutide) demonstrated cardiovascular risk reduction independent of glucose control. Emerging research examines GLP-1 agonists in Alzheimer disease models, Parkinson disease, and MASH/NAFLD.

These indications are under active clinical investigation and are not approved uses of research-grade materials. Educational context only.

DPP-4 inhibitors (sitagliptin, saxagliptin) prevent breakdown of endogenous GLP-1, modestly raising its levels. GLP-1 receptor agonists provide supraphysiologic receptor activation. The clinical magnitude of effect differs substantially: GLP-1 RAs produce 5–15%+ weight loss in trials; DPP-4 inhibitors are generally weight-neutral.

Both target the GLP-1 pathway but at different points—enzyme inhibition vs direct receptor agonism. For metabolic peptide research context, see weight management category.

RUO materials discussed on this site are not for human consumption. For dual GIP/GLP-1 vs GLP-1-only context, see tirzepatide vs semaglutide. For metabolic research shopping: weight management research and deals (SOL code). We may earn from qualifying purchases.